Expanding Options for Treatment of CLL Using BTK Inhibitors
EP. 1: BTK-Targeted Therapy for CLL
By
Targeted Oncology
May 8th 2020
EP. 2: Acalabrutinib Versus Ibrutinib for CLL
By
Targeted Oncology
May 8th 2020
EP. 3: Acalabrutinib Treatment Considerations in CLL
By
Targeted Oncology
May 8th 2020
EP. 4: Selecting Frontline Therapy for CLL
By
Targeted Oncology
May 8th 2020
EP. 5: MRD and 11q Deletions in CLL
By
Targeted Oncology
May 8th 2020
EP. 6: BTK Inhibitors for Elderly Patients With CLL
By
Targeted Oncology
May 8th 2020
EP. 7: Long-Term Experience With BTK Inhibitors for CLL
By
Targeted Oncology
May 8th 2020
EP. 8: Combination Therapies With BTK Targeted Therapy in CLL
By
Targeted Oncology
May 8th 2020
EP. 9: BTK Inhibition in CLL: Real-World Data
By
Targeted Oncology
May 8th 2020
EP. 10: Resistance to BTK Targeted Therapy in CLL
By
Targeted Oncology
May 8th 2020
EP. 11: Treating CLL With BTK Inhibition: Next Steps
By
Targeted Oncology
May 8th 2020
